MicroRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma

Rheumatology (United Kingdom)

Volumn 51, Issue 9, 2012, Pages 1550-1556

  Sing, Takaomi ^a   Jinnin, Masatoshi ^a   Yamane, Keitaro ^a   Honda, Norihito ^a   Makino, Kastunari ^a   Kajihara, Ikko ^a   Makino, Takamitsu ^a   Sakai, Keisuke ^a   Masuguchi, Shinichi ^a   Fukushima, Satoshi ^a   Ihn, Hironobu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Collagen disease; Integrin; PCR

Indexed keywords

COLLAGEN; INTERSTITIAL COLLAGENASE; MICRORNA; MICRORNA 135; MICRORNA 92A; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCLERODERMA; SKIN FIBROBLAST;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CELLS, CULTURED; DERMATOMYOSITIS; DERMIS; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; INTEGRIN ALPHAVBETA3; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MATRIX METALLOPROTEINASE 1; MICRORNAS; MIDDLE AGED; RNA, SMALL INTERFERING; SCLERODERMA, DIFFUSE; SCLERODERMA, LOCALIZED; TRANSFORMING GROWTH FACTOR BETA;

EID: 84865322922     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes120     Document Type: Article

References (27)

1. Korn JH. Immunologic aspects of scleroderma. Curr Opin Rheumatol 1989;1:479-84.
2. Mauch C, Krieg T. Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis. Rheum Dis Clin North Am 1990;16:93-107.
3. Massague J. Transforming growth factor-ß family. Ann Rev Cell Biol 1990;6:597-641.
4. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974;54:880-9.
5. Jimenez SA, Feldman G, Bashey RI et al. Co-ordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis. Biochem J 1986; 237:837-43.
6. Ihn H, Yamane K, Kubo M et al. Blockade of endogenous transforming growth factor ß signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor ß receptors. Arthritis Rheum 2001; 44:474-80.
7. Asano Y, Ihn H, Yamane K et al. Involvement of avß5 integrin-mediated activation of latent transforming growth factor ß1 in autocrine transforming growth factor ß signaling in systemic sclerosis fibroblasts. Arthritis Rheum 2005;52:2897-905.
8. Asano Y, Ihn H, Jinnin M, Mimura Y, Tamaki K. Involvement of avß5 integrin in the establishment of autocrine TGF-ß signaling in dermal fibroblasts derived from localized scleroderma. J Invest Dermatol 2006;126:1761-9.
9. Asano Y, Ihn H, Yamane K et al. Increased expression of integrin avß5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 2006;168:499-510.
10. Asano Y, Ihn H, Yamane K et al. Increased expression of integrin avß3 contributes to the establishment of autocrine TGF-ß signaling in scleroderma fibroblasts. J Immunol 2005;175:7708-18.
11. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
12. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-6.
13. Ihn H, Sato S, Fujimoto M et al. Measurement of anticardiolipin antibodies by ELISA using ß2-glycoprotein I (ß2-GPI) in systemic sclerosis. Clin Exp Immunol 1996;37: 1188-92.
14. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
15. Maricq HR, Weinrich MC, Keil JE et al. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989;32: 998-1006.
16. Maricq HR, McGregor AR, Diat F et al. Major clinical diagnoses found among patients with Raynaud phenomenon from the general population. J Rheumatol 1990;17: 1171-6.
17. Ihn H, Sato S, Tamaki T et al. Clinical evaluation of scleroderma spectrum disorders using a points system. Arch Dermatol Res 1992;284:391-5.
18. Kroh EM, Parkin RK, Mitchell PS et al. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010;50:298-301.
19. Zhu W, Qin W, Atasoy U et al. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2009; 2:89.
20. Gilad S, Meiri E, Yogev Y et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008;3:e3148.
21. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105: 10513-8.
22. Kanemaru H, Fukushima S, Yamashita J et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci 2011;61: 187-93.
23. Hayashi N, Koshiba M, Nishimura K et al. Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period. Mod Rheumatol 2008;18:153-60.
24. Friedman RC, Farh KK, Burge CB et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
25. Kuehbacher A, Urbich C, Dimmeler S. Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci 2008;29:12-5.
26. Furer V, Greenberg JD, Attur M et al. The role of microRNA in rheumatoid arthritis and other autoimmune diseases. Clin Immunol 2010;136:1-15.
27. Kuroda K, Shinkai H. Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997; 289:567-72.